Topotecan HCl

Catalog No.S1231 Synonyms: NSC609699, Nogitecan HCl, SKFS 104864A

Topotecan HCl Chemical Structure

Molecular Weight(MW): 457.91

Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 230 In stock
USD 180 In stock
USD 320 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Cells were treated at the same concentrations as in Caspase3/7 assay for 16 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control.

    BMC Cancer, 2015, 10.1186/s12885-015-1231-z. Topotecan HCl purchased from Selleck.

    Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of topotecan by 4.8 fold, respectively, yet did not affect the IC50 of mafosfamide.

    PLoS Genet 2014 10(1), e1004107. Topotecan HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.
Features Topotecan is a water-soluble derivative of camptothecin.
Targets
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
In vitro

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells M4HIU2N6fG:2b4jpZ:Kh[XO|YYm= MV63NkBp NUHZVHdvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBq[zVyPUGgcm0> MoTQNlA{PzFzOEO=
human Bel7402 cells MXPDfZRwfG:6aXRCpIF{e2G7 NVPLdGhqQTZiaB?= NVzpfJI{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSmWuN{SwNkBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTFwMjDuUS=> NHvpVlQyPTF4NUG0OC=>
human HCT8 cells NH\UcZJEgXSxdH;4bYPDqGG|c3H5 NE\nVZc6PiCq NEnjZYJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU42KG6P NWfKdnhTOTVzNkWxOFQ>
human MCF7 cells MkTBR5l1d3SxeHnjxsBie3OjeR?= M3nzR|k3KGh? NHfqOolEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU45KG6P MnzWNVUyPjVzNES=
human A549 cells M4D6WmN6fG:2b4jpZ:Kh[XO|YYm= NYnuR|J5QTZiaB?= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Mz6yJI5O NXjlUZFFOTVzNkWxOFQ>
human colon carcinoma SW620 cell MoHpR5l1d3SxeHnjxsBie3OjeR?= NYO5eGN6S3m2b4TvfIlkKHCxdHXueIlifGmxbjDv[kBVd3CxdHXjZY4hMFSSKTDifUB1cGViY3;tdI92dmRiaX6gbJVu[W5iY3;sc44h[2G{Y3nuc41iKFOZNkKwJINmdGxibHnu[UwhUUN3ME2zMlIhdk1? MnLKNVI1ODh5MEe=
human MESSA cells MlTwR5l1d3SxeHnjxsBie3OjeR?= NXizWVYyPzJiaB?= MlXZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUW0FiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUSgcm0> Ml22NlE{PDF4N{S=
human BGC823 cells NXjBcmM3S3m2b4TvfIlkyqCjc4PhfS=> M3HuUFk3KGh? NHTvZmdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDT0N6MkOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01NjNibl2= NHjU[ZoyPTF4NUG0OC=>
human Ketr3 cells NV73XWhZS3m2b4TvfIlkyqCjc4PhfS=> MlTkPVYhcA>? M2XO[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmfHJ|IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE46KG6P NWiwUlFrOTVzNkWxOFQ>
LOX cells MXHDfZRwfG:6aXRCpIF{e2G7 NHfFR2NEgXSxdH;4bYNqfHlid3HzJIRmfGW{bXnu[YQhcW5idnn0do8hcW5iTF;YJINmdGy|IDjt[Yxidm:vYTmgc4YhcHWvYX6geJVud3JiY3XscEBtcW6nczDifUB2e2mwZzDNWHQh[XO|YYmsJGlEPTB;NTDuUS=> M37L[|c5PTN|M{G=
human A549 cells NHv6cFlHfW6ldHnvckBie3OjeR?= NIPocGs1KGh? Mnq3RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PSCwTR?= NYPBbFZEOTh{MEe3OFg>
human H69 cells NYrDb5dSS3m2b4TvfIlkyqCjc4PhfS=> NXXjNnQyPzJiaB?= NGnjdXJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPjliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPU[gcm0> Mn\ONlE{PDF4N{S=
human A2780 cells NVXsRpppS3m2b4TvfIlkyqCjc4PhfS=> MoDTO|IhcA>? NEL0S3dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCxdnXy[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9OkBvVQ>? NIjNNY0zOjl3OUK0Oi=>
human LNCAP cells M4D1eGN6fG:2b4jpZ:Kh[XO|YYm= NUGxN41IPzJiaB?= MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;OTDuUS=> NXvmenBWOjF|NEG2O|Q>
human HOP62 cells NFPXRolIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHWS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTG9RPjJiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P MUeyOVkxQTJ5OR?=
human MCF7 cells NI\pc4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYO0UpJzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFnDOVA:OTBibl2= MlLONlU6ODl{N{m=
human UACC62 cells MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;OS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWWFESzZ{IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiSVO1NF0yOCCwTR?= M{DUZ|I2QTB7Mke5
human DU145 cells NWLiNplJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? MX2yOVkxQTJ5OR?=
LoVo cell line M1TIemN6fG:2b4jpZ:Kh[XO|YYm= MVrDfZRwfG:6aXOgdI91\W62aXH0bY9vKG:oIGTvdI91\WOjbjCoWHAqKGK7IITo[UBkd22yb4Xu[EBqdiBqaIXtZY4h[2:ub4LlZ5RidCClYX7j[ZIhVG:YbzDj[YxtKGyrbnWsJGlEPTB;MUGuOkBvVQ>? NX3rXphpOTJ2MEi3NFc>
human lymphoblast tumor cell line RPM18402 M2[0[2N6fG:2b4jpZ:Kh[XO|YYm= NGnrN2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtgW2yaH;icIF{fCC2dX3vdkBk\WyuIHzpcoUhWlCPMUi0NFItKEmFNUC9NVIhdk1? M{fWfFEzOzl{N{S1
human HL60 cells MkPPSpVv[3Srb36gZZN{[Xl? M{j1U2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZpkhW1KEIH3leIhw\CxiSVO1NF0yOiCwTR?= M1TkVlE6PTRzNEiz
human A375 cells NFK5XoVEgXSxdH;4bYPDqGG|c3H5 NGDMd4w4OiCq MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OD1zMzDuUS=> MWOyNVM1OTZ5NB?=
COR-L23/P cell NWiyS3NyS3m2b4TvfIlkyqCjc4PhfS=> MXnDfZRwfG:6aXPpeJkhdWWjc4Xy[YQhfXOrbnegeIhmKEORUj3MNlMheGG{ZX70ZYwhMEORUj3MNlMwWCliaIXtZY4hdm:wIIPtZYxtKGOnbHygcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nLDDJR|UxRTF|LkKgcm0> MWqxNVgxPjd{NB?=
human NCI-H460 cells NUexSJlNWHKxbHnm[ZJifGmxbjDhd5NigQ>? MYO3NkBp NG\OU2JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBkd3WudHXyJINwfW62ZYKgZY5idHm|aYOsJGlEPTB;MU[gcm0> NWPDTnVkOjF5OEOzOlk>
human MOLT4 cells MUjDfZRwfG:6aXRCpIF{e2G7 NUHk[3hyPzJiaB?= MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG5JI5O MnXzNlQ6ODB5MkW=
human LoVo cells MmH6R5l1d3SxeHnjxsBie3OjeR?= MWC3NkBp NHn5XlhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNd1[xIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NlAhdk1? M{PvNFIxOzdzMUiz
RPM18402 tumor cell line MWHQdo9tcW[ncnH0bY9vKGG|c3H5 NXfhVXFHS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JINmdGxicILvcIln\XKjdHnvckBqdiCUUF2xPFQxOiC2dX3vdkBk\WyuIHzpcoUtKEmFNUC9NlAhdk1? NHq3e4EyPTR6MkmyPS=>
human SN12C cells M4XQeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml;4S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV24yOkNiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVIxKG6P M1PzcFI2QTB7Mke5
human RPMI8226 cells MX7DfZRwfG:6aXRCpIF{e2G7 NXu4RVF{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWlCPSUiyNlYh[2WubIOgZpkhVVSWIH3leIhw\CxiSVO1NF0zOSCwTR?= MYSxPVAyOjl7Nh?=
HT-29 cells MX3DfZRwfG:6aXRCpIF{e2G7 MVzDfZRwfG:6aXPpeJkhf2G|IHTleIVzdWmwZXSgbY4hfmm2cn:gbY4hUFRvMkmgZ4VtdHNqY3;sc44qKG:oIHj1cYFvKHS3bX;yJINmdGxibHnu[ZMh[nlidYPpcochVVSWIHHzd4F6NCCLQ{WwQVI2KG6P NU\RTm1oPzh3M{OzNS=>
SK-BR-3 cells NY\0cIhbS3m2b4TvfIlkyqCjc4PhfS=> MlLOTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsJIxqdmViKGPLMWJTNTNrLDDJR|UxRTJ4IH7N MYixNVM{PDV4OR?=
HeLa cells M2G2eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXr1Z5pqT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSHXMZUBk\WyuczDh[pRmeiB2IHThfZMtKEeLNUC9N|Ahdk1? NGLUdmkyPzRzOEW4Ni=>
UACC 62 cells MV7DfZRwfG:6aXRCpIF{e2G7 M3nrSnRme3SnZDDpckB3cXS{bzDmc5Ih[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfHWvb4KgZ4VtdCCuaX7lJHVCS0NiNkKgLI1mdGGwb33hLUwhT0l3ME2zNEBvVQ>? MoTUNVA4OTR3MEK=
human HCT116 cells NXnk[2g{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV;BPXVFT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IHL5JIZqfmVvZH;z[UBoem:5dHigbY5pcWKrdHnvckBie3OjeTygS2k2OD1|MDDuUS=> M3LxPFI2QTB7Mke5
human lung cancer cell line (H128) NETVdphEgXSxdH;4bYPDqGG|c3H5 MYHJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDseY5oKGOjbnPldkBk\WyuIHzpcoUhMEhzMkipMEBKSzVyPUOxJI5O M3jScFEyOzN2NU[5
human MES-SA/Dx5 cells MkOwR5l1d3SxeHnjxsBie3OjeR?= NHrKN2tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzJI93\XKneIDy[ZN{cW6pIF3EVlEh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUOzJI5O MnO0NlE{PDF4N{S=
human A2780 cells NFy5NGpEgXSxdH;4bYPDqGG|c3H5 NFP0e|Q4OiCq NYrq[mxMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0{OyCwTR?= MYmyOFkxODd{NR?=
human MDA-MB-435 cells M2LKZWN6fG:2b4jpZ:Kh[XO|YYm= MmLMO|IhcA>? NXu4cpcyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTB;M{Sgcm0> NUfXdXNwOjJ6NkewNVk>
human stomach cancer cell line (MKN45) NWf6WmZHS3m2b4TvfIlkyqCjc4PhfS=> NVTGS5VMUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4he3SxbXHjbEBk[W6lZYKgZ4VtdCCuaX7lJEhOU052NTmsJGlEPTB;M{igcm0> NYfPSplKOTF|M{S1Olk>
human KB3-1 cells MmHmR5l1d3SxeHnjxsBie3OjeR?= M3;3XGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDOy1zIHPlcIx{KGGodHXyJG1VXCCjc4PhfUwhUUN3ME20NEBvVQ>? MlXYNVg5Ojl|M{S=
mouse P388 cells M4K0dWN6fG:2b4jpZ:Kh[XO|YYm= MoHjR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVFM5QCClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NEWgcm0> M2jIdFE5QDJ7M{O0
A427 human lung carcinoma MUDQdo9tcW[ncnH0bY9vKGG|c3H5 MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDt[YF{fXKnZDDh[4FqdnO2IFG0NlchcHWvYX6gcJVv\yClYYLjbY5wdWFuIFnDOVA:PDlibl2= NXHhdoFoQTh5NkGxNS=>
human U251 cells NVr1eVlJTnWwY4Tpc44h[XO|YYm= MW[2MVI1KGh? M4S0XmlvcGmkaYTpc44hd2ZidH;wc4l{d22ncnHz[U0yKGmwIHj1cYFvKFV{NUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmILUHhcJBp[SCjY3P1cZVt[XSrb36gbY4hdnWlbHXhdkBmgHS{YXP0JIFnfGW{IE[geI8hOjRiaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXNuIFXDOVA:PTRibl2= NXnJfJlsOjJ|MEW2NVI>
human colon cancer cell line (WiDr) NIT1dWZEgXSxdH;4bYPDqGG|c3H5 MljYTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9OVYhdk1? Ml\uNVE{OzR3Nkm=
human HepG2 cells MkHhR5l1d3SxeHnjxsBie3OjeR?= Ml;IOEBl[Xm| M1XVRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9OlAhdk1? MU[xPFU2PDlyNh?=
human KB cells MVjDfZRwfG:6aXRCpIF{e2G7 NVLnPJBUPzJiaB?= MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUC9OlIvPSCwTR?= M4np[|I2ODB6NEW2
human HCT8 cells NFG5XWxEgXSxdH;4bYPDqGG|c3H5 NXfaPGt1OyCmYYnz MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;N{Cgcm0> M2PJ[|IxOzl{NUS1
human GBM2 cells MUPQdo9tcW[ncnH0bY9vKGG|c3H5 M{TWN|czKGh? MoDsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2yJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9NE4yOyEQvF2= NGDISWszPjN3NUWzNi=>
SK-MEL-2 cells NUDXRoFZS3m2b4TvfIlkyqCjc4PhfS=> M3fnblczKGh? NFy5b3REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2PRVytNkBk\WyuczDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVA:OC5zNDFOwG0> MWWyNVM1OTZ5NB?=
human IGROV1 cells M1;QUGN6fG:2b4jpZ:Kh[XO|YYm= MYS3NkBp M3HYNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlIWk:YMTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9NE4yPiEQvF2= NX7XPW55OjF|NEG2O|Q>
human U87 cells NFnVUmhRem:uaX\ldoF1cW:wIHHzd4F6 NYG0Z|gyPDhiaB?= NI\SRVNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVYh|ryP Mki2NlQ5OjZ6MUi=
human HT1080 cells NV32fmJWWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4TtOlQ5KGh? M2HGV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSxNFgxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OC5zODFOwG0> NIWwe4UzPjRyOEixOS=>
human Hep3B cells MUTQdo9tcW[ncnH0bY9vKGG|c3H5 NEXMb2Q4OiCq MkD6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYCzRkBk\WyuczDh[pRmeiB5MjDodpMh[nliWGTUJIF{e2G7LDDHTVUxRTBwMkKg{txO Ml;KNVk4QTZ7NU[=
human GBM3 cells MWXQdo9tcW[ncnH0bY9vKGG|c3H5 Ml;CO|IhcA>? M1TyXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVAvOzhizszN MYqyOlM2PTV|Mh?=
human KBVIN cells MWnDfZRwfG:6aXRCpIF{e2G7 M1nmdVczKGh? NX3pclJ2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0KYSV6gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjRizszN NVf6[FBSOjV2M{i3Olk>
human GBM1 cells M4PFW3Bzd2yrZnXyZZRqd25iYYPzZZk> NYnVRm57PzJiaB?= NG\aZVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfCUVEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHdUXC1zIH3leIhw\CxiSVO1NF0xNjR4IN88US=> Mn3VNlY{PTV3M{K=
human U937 cells NHHSZ|NEgXSxdH;4bYPDqGG|c3H5 NUX3dZE6PDhiaB?= NWrpVpIzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTl|NzDj[YxteyCneIDy[ZN{cW6pIIC1N{BufXSjboSgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTFvwKwhUUN3ME2xMlEh|ryP MX6xPVcyPTNzOR?=

... Click to View More Cell Line Experimental Data

In vivo Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7 Luc and DU-145 Luc cells
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96 hours
  • Method:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice with MCF-7 Luc or DU-145 Luc cells
  • Formulation: PBS
  • Dosages: 0.25 mg/mL
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (200.91 mM)
Water 92 mg/mL (200.91 mM)
Ethanol <1 mg/mL
In vivo Saline 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 457.91
Formula

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage powder
in solvent
Synonyms NSC609699, Nogitecan HCl, SKFS 104864A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT00117013 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 28, 2005 Phase 1
NCT02980809 Not yet recruiting Small Cell Lung Cancer First Hospitals affiliated to the China PLA General Hospital March 2017 Phase 2
NCT02963090 Not yet recruiting Small Cell Lung Cancer Alliance Foundation Trials, LLC.|Merck Sharp & Dohme Corp. December 2016 Phase 2
NCT02348398 Withdrawn Cervical Cancer M.D. Anderson Cancer Center|GlaxoSmithKline August 2016 Phase 2
NCT02822157 Not yet recruiting Ovarian Epithelial Cancer Universitaire Ziekenhuizen Leuven|AstraZeneca August 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Topotecan HCl | Topotecan HCl supplier | purchase Topotecan HCl | Topotecan HCl cost | Topotecan HCl manufacturer | order Topotecan HCl | Topotecan HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID